Home > Haematology > EHA 2020 > CML TKI interruption: Swedish registry results

CML TKI interruption: Swedish registry results

With a median follow-up of 9 years, discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic phase chronic myeloid leukaemia (CML) was reported in 43% of 548 evaluable CML patients, in a population-based setting. Patients interrupting TKI therapy outside a clinical trial setting had good outcomes.

Dr Hjalmar Flygt (Uppsala University Hospital, Sweden) presented data extracted from the Swedish CML registry about patients stopping TKI therapy outside of clinical trials in chronic phase CML [1]. Studies have shown that 40-50% of patients with a deep molecular response (DMR, defined as MR4.0 or lower) successfully remained TKI treatment-free. In the current Swedish Guidelines for CML, stopping TKI therapy can be considered in patients treated with a TKI ≥5 years and an MR4.0 or lower for at least 2 years.

CML patients diagnosed between 2007-2012 (n=584) were analysed, of whom 234 of the 548 evaluable patients (43%) had...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on